ExcelFin Acquisition Price, Forecast, Insider, Ratings, Fundamentals & Signals

Baird medical agreed to subject 30% of its shares to be received in the transaction to an earnout at a $12.50 trading price minimum cash condition of $15 million has been waived, cementing certainty and expediency to our transaction close upon closing, baird medical is expected to trade on nasdaq under the ticker symbol "bdmd" fort mill, s.c. , march 12, 2024 /prnewswire/ -- betters medical investment holdings limited ("baird medical" or the "company"), a leading microwave ablation ("mwa") medical device developer and provider in china and the united states, and excelfin acquisition corp. ("excelfin") (nasdaq: xfin), a publicly traded special purpose acquisition company, today announced a strategic update to their previously announced business combination agreement.

New york , oct. 17, 2023 /prnewswire/ -- excelfin acquisition corp. ("we", "us", "our", or the "company"), today announced that the special meeting originally scheduled for october 18, 2023 (the "special meeting") is being adjourned to october 20, 2023. at the special meeting, the company's stockholders will be asked: to consider and vote upon a proposal to amend the company's amended and restated certificate of incorporation (the "charter") pursuant to a second amendment to the charter (the "extension amendment") to extend the date by which the company must effectuate an initial business combination from october 25, 2023 (the "termination date") to april 25, 2024, comprised of an initial three-month extension and three subsequent one-month extensions, for a total of six months after the termination date (assuming the company's initial business combination has not occurred); and to consider and vote upon a proposal to adjourn the special meeting to a later date or dates, if necessary, to (i) permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the special meeting, there are not sufficient votes to approve one or more proposals presented to stockholders for vote or (ii) if stockholders have elected to redeem an amount of shares in connection with the extension amendment such that the company would not adhere to the continued listing requirements of the nasdaq global market ("nasdaq") (the "adjournment proposal").